| Methods |
3‐week placebo run‐in; inclusion criteria= supine DBP 100‐110 mm Hg during run‐in; 4‐week double‐blind treatment |
| Participants |
All patients: n=152(77 males,75 females); mean age=69(4) years;
Captopril 25 mg: n=52; baseline standing SBP=173(13) mm Hg, DBP=106(5) mm Hg; baseline supine SBP=176(14) mm Hg, DBP=105(5) mm Hg;
Placebo: n=50; baseline standing SBP=172(14) mm Hg, DBP=106(5) mm Hg; baseline supine SBP=176(14) mm Hg, DBP=104(5) mm Hg; |
| Interventions |
Captopril 25 mg twice daily;
Placebo |
| Outcomes |
Standing SBP/DBP using mercury sphygmomanometer;
Supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change in captopril group; imputed baseline SBP SD for SBP SD of change in placebo group; in placebo group, imputed systematic review overall mean SD of change for DBP; BP data from text and Figure 1, p. S600; baseline supine SBP/DBP and SD for placebo group from Table 1, p. S601; supine BP data also available; Jadad score=3; funding source= Squibb Italia SpA |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
